Health and Healthcare

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

256 Articles

Trey Thoelcke | Jun 11, 2014 at 10:15 AM EDT

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in…

Jon C. Ogg | Jun 10, 2014 at 8:20 AM EDT

After Idenix: The Next Four Biotech Buyout Candidates

Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at…

Jon C. Ogg | May 8, 2014 at 8:35 AM EDT

RBC Doctor Panel Picks in Drugs and Biotech

In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six…

Trey Thoelcke | Apr 9, 2014 at 8:45 AM EDT

These Top Stocks Are Cheap After Huge Market Sell-Off

ThinkstockIn just a matter of days, the S&P 500 managed to produce a sell-off of more than 6%. The equity…

Trey Thoelcke | Mar 11, 2014 at 8:45 AM EDT

Catalysts That Could Push Top Biotech Stocks Even Higher

Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In…

Trey Thoelcke | Jan 29, 2014 at 8:15 AM EST

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…

Jon C. Ogg | Jan 14, 2014 at 8:15 AM EST

UBS Has Nine Biotech Buyout and Merger Candidates

The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility…

Jon C. Ogg | Jan 8, 2014 at 8:10 AM EST

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going…

Jon C. Ogg | Jan 6, 2014 at 9:00 AM EST

Ten Top Growth Stock Ideas for 2014 From Baird

Baird offers an eclectic and interesting list for investors. A top regional firm, it tends to dig a little deeper,…

Jon C. Ogg | Jan 6, 2014 at 8:45 AM EST

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

These are the top analyst upgrades, initiations and positive analyst research calls seen from Wall Street on Monday, January 6.

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Nov 2, 2013 at 7:15 AM EDT

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

ThinkstockIdenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on Friday with a rally of 40%.…

Lee Jackson | Sep 4, 2013 at 8:25 AM EDT

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive…

Jon C. Ogg | Aug 22, 2013 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Jon OggNow that stocks have pulled back and interest rates have risen, investors are looking for more guidance on which…

Jon C. Ogg | Jul 12, 2013 at 8:15 AM EDT

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that…

1 … 10 11 12 13 14 … 18

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

After Idenix: The Next Four Biotech Buyout Candidates

RBC Doctor Panel Picks in Drugs and Biotech

These Top Stocks Are Cheap After Huge Market Sell-Off

Catalysts That Could Push Top Biotech Stocks Even Higher

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

UBS Has Nine Biotech Buyout and Merger Candidates

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Ten Top Growth Stock Ideas for 2014 From Baird

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

A Caller’s Dad Turned $22,000 Into $1 Million on a Single Stock. Now the Family Faces a $150,000 Tax Decision

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

After Idenix: The Next Four Biotech Buyout Candidates

RBC Doctor Panel Picks in Drugs and Biotech

These Top Stocks Are Cheap After Huge Market Sell-Off

Catalysts That Could Push Top Biotech Stocks Even Higher

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

UBS Has Nine Biotech Buyout and Merger Candidates

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Ten Top Growth Stock Ideas for 2014 From Baird

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

A Caller’s Dad Turned $22,000 Into $1 Million on a Single Stock. Now the Family Faces a $150,000 Tax Decision

Featured Reads

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60